A Case of Graves’ Thrombosis?
Back to list
Case Series
A Case of Graves’ Thrombosis?
Sara‐Joan Pinto‐Sietsma 1, Victor Gerdes 2, Esther Bouwmans 3, Karly Hamulyak 4, A Abraham Kroon 1 and Hugo ten Cate 1
Affiliations: 1 Division of Vascular Medicine, Department of Internal Medicine, Academic Hospital Maastricht and 2 Department of Internal Medicine, Slotervaart Hospital, and Consultant in Vascular Medicine, Academic Medical Centre and 3 Department of Internal Medicine, VieCuri Medical Centre and 4 Division of Hematology, Department of Internal Medicine, Academic Hospital Maastricht
Correspondence: Sara‐Joan Pinto‐Sietsma, Division of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre, Meibergdreef 9, PO Box 22660, 1105 AZ, Amsterdam, The Netherlands
CASE: THE PRESENTATION
A 42-year-old woman was admitted to our hospital with acute onset cold, blue, and painful fingers of her right hand, which started the day before. Except for hypertension, diagnosed several years ago, her medical history was unremarkable. There were no previous signs of fever, arm claudication, or Raynaud’s phenomenon, except for proximal muscle pain in both arms which had existed for 5 weeks. Her weight had remained stable over the past several years and, apart from a slight exophthalmos, there were no other clinical signs of hyperthyroidism. Her family history was negative for thrombosis or atherosclerosis and she smoked 25 cigarettes/day. Furthermore, she used omeprazole (40 mg/day), hydrochlorothiazide (25 mg/ day), and depot medroxyprogesterone.
Other Articles
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors
- Decreased Bone Mineral Density in Adult Patients with Hemophilia: Clinical Significance, Prevalence and Risk Factors
- Safety of Recombinant Factor VIII Therapy: Focus on Inhibitor Development
